Search

Your search keyword '"Drospirenone -- Intellectual property"' showing total 61 results
Start Over Descriptor "Drospirenone -- Intellectual property"
61 results on '"Drospirenone -- Intellectual property"'

1. Researchers Submit Patent Application, 'Composite Drug Particles And Uses Thereof', for Approval (USPTO 20240165130)

Subjects
Nandrolone -- Intellectual property, Tixocortol, Drospirenone -- Intellectual property, Corticosteroids -- Intellectual property, Hydroxyprogesterone -- Intellectual property, Ciclesonide, Fludrocortisone, Estropipate -- Intellectual property, Androgens, Drug approval, Physical fitness, Oral contraceptives -- Intellectual property, Health
Abstract

2024 JUN 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- From Washington, D.C., NewsRx journalists report that a patent application by the [...]

Published
2024

2. Researchers Submit Patent Application, 'Use Of Combined Oral Contraceptives Containing Nomegestrol Acetate And Estradiol', for Approval (USPTO 20230398127)

Subjects
Estradiol -- Intellectual property, Women -- Health aspects, Drospirenone -- Intellectual property, Phenols -- Intellectual property, Contraceptives -- Intellectual property, Acetates -- Intellectual property, Health, Women's issues/gender studies
Abstract

2024 JAN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventor BOOLELL, [...]

Published
2024

3. Researchers Submit Patent Application, 'Methods Of Contraception Using Nomegestrol Acetate And Estradiol', for Approval (USPTO 20230390306)

Subjects
Estradiol -- Intellectual property, Women -- Health aspects, Drospirenone -- Intellectual property, Phenols -- Intellectual property, Contraceptives -- Intellectual property, Norgestimate -- Intellectual property, Transdermal medication -- Intellectual property, Acetates -- Intellectual property, Health, Women's issues/gender studies
Abstract

2023 DEC 28 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventor BOOLELL, [...]

Published
2023

4. Researchers Submit Patent Application, 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same', for Approval (USPTO 20230372248)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2023 DEC 14 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors DROUIN, [...]

Published
2023

5. Mithra's Nextstellis granted additional patent in US

Subjects
Drospirenone -- Intellectual property, Estrogen, Pharmaceuticals and cosmetics industries, Nextstellis (Contraceptive) -- Intellectual property
Abstract

Mithra, a company dedicated to women's health, announces that it has been granted an additional patent for Nextstellis (3 mg drospirenone and 14.2 mg estetrol (E4) tablets) in the United [...]

Published
2023

8. 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same' in Patent Application Approval Process (USPTO 20230046871)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2023 MAR 9 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors DROUIN, Dominique (Verrieres-le-Buisson, FR); PERRIN, Philippe (Paris, FR); [...]

Published
2023

12. 'Use Of Neuropilin Antagonists For The Treatment Of Endometriosis' in Patent Application Approval Process (USPTO 20230000832)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Hydroxyprogesterone -- Intellectual property, Norgestimate -- Intellectual property, Cell receptors, Endometriosis, Health, Women's issues/gender studies
Abstract

2023 JAN 26 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors GOGUSEV, Jean (Paris, FR); LEPELLETIER, Yves (Paris, FR); [...]

Published
2023

13. Patent Issued for Synthetic progestogens and pharmaceutical compositions comprising the same (USPTO 11504334)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 DEC 15 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by [...]

Published
2022

14. Patent Issued for Synthetic progestogens and pharmaceutical compositions comprising the same (USPTO 11491113)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 DEC 1 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by [...]

Published
2022

16. Researchers Submit Patent Application, 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same', for Approval (USPTO 20220339107)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 NOV 17 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors DROUIN, [...]

Published
2022

17. Patent Application Titled 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same' Published Online (USPTO 20220339106)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 NOV 17 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

Published
2022

18. 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same' in Patent Application Approval Process (USPTO 20220339165)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 NOV 17 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors DROUIN, Dominique (Verrieres-le-Buisson, FR); PERRIN, Philippe (Paris, FR); [...]

Published
2022

19. Mithra's NEXTSTELLIS(r) granted additional patent in the United States

Subjects
Euronext Brussels S.A./N.V. -- Intellectual property, Drospirenone -- Intellectual property, Securities industry -- Intellectual property, Securities industry, General interest, News, opinion and commentary, Nextstellis (Contraceptive) -- Intellectual property
Abstract

Liege: Mithra Pharmaceuticals has issued the following news release: Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, announces today that it has been granted an additional patent for [...]

Published
2023

20. Mithra's NEXTSTELLIS(R) granted additional patent in the United States

Subjects
Euronext Brussels S.A./N.V. -- Intellectual property, Women -- Health aspects, Drospirenone -- Intellectual property, Securities industry -- Intellectual property, Securities industry, Business, international, Nextstellis (Contraceptive) -- Intellectual property
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Mithra's NEXTSTELLIS(R) granted additional patent in the United States - New patent extends protection for NEXTSTELLIS(R) (ESTELLE(R)) until 2036 - Mayne Pharma has a 20-year [...]

Published
2023

21. Mithra's NEXTSTELLIS(R) granted additional patent in the United States

Subjects
Euronext Brussels S.A./N.V. -- Intellectual property, Women -- Health aspects, Drospirenone -- Intellectual property, Securities industry -- Intellectual property, Securities industry, Banking, finance and accounting industries, Business, Nextstellis (Contraceptive) -- Intellectual property
Abstract

Mithra's NEXTSTELLIS [sup. (R) ] granted additional patent in the United States New patent extends protection for NEXTSTELLIS [sup. (R) ] (ESTELLE [sup. (R) ] ) until 2036 Mayne Pharma [...]

Published
2023

22. Patent Issued for Synthetic progestogens and pharmaceutical compositions comprising the same (USPTO 11452695)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 OCT 20 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent by the inventors Drouin, Dominique (Verrieres-le-Buisson, FR), Perrin, Philippe (Paris, FR), Velada, [...]

Published
2022

24. Patent Issued for Synthetic progestogens and pharmaceutical compositions comprising the same (USPTO 11439598)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 OCT 6 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent by the inventors Drouin, Dominique (Verrieres-le-Buisson, FR), Perrin, Philippe (Paris, FR), Velada, [...]

Published
2022

25. Researchers Submit Patent Application, 'Composite Drug Particles And Uses Thereof', for Approval (USPTO 20220257523)

Subjects
Nandrolone -- Intellectual property, Tixocortol, Drospirenone -- Intellectual property, Corticosteroids -- Intellectual property, Hydroxyprogesterone -- Intellectual property, Estropipate -- Intellectual property, Ciclesonide, Fludrocortisone, Androgens, Drug approval, Physical fitness, Oral contraceptives -- Intellectual property, Health
Abstract

2022 SEP 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- From Washington, D.C., NewsRx journalists report that a patent application by the [...]

Published
2022

26. 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same' in Patent Application Approval Process (USPTO 20220241209)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors DROUIN, Dominique (Verrieres-le-Buisson, FR); PERRIN, Philippe (Paris, FR); [...]

Published
2022

27. Researchers Submit Patent Application, 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same', for Approval (USPTO 20220218615)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 AUG 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors DROUIN, [...]

Published
2022

28. 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same' in Patent Application Approval Process (USPTO 20220192991)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors DROUIN, Dominique (Verrieres-le-Buisson, FR); PERRIN, Philippe (Paris, FR); [...]

Published
2022

29. Researchers Submit Patent Application, 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same', for Approval (USPTO 20220183984)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 JUL 7 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors DROUIN, [...]

Published
2022

30. Patent Issued for Synthetic progestogens and pharmaceutical compositions comprising the same (USPTO 11351122)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 JUN 30 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by [...]

Published
2022

31. Mithra Pharmaceuticals granted new US patent extending NEXTSTELLIS protection until 2036

Subjects
Euronext Brussels S.A./N.V. -- Intellectual property, Drospirenone -- Intellectual property, Securities industry -- Intellectual property, Securities industry, Business, Nextstellis (Contraceptive) -- Intellectual property
Abstract

M2 EQUITYBITES-November 7, 2023-Mithra Pharmaceuticals granted new US patent extending NEXTSTELLIS protection until 2036 (C)2023 M2 COMMUNICATIONS http://www.m2.co.uk Belgian biopharmaceutical company Mithra Pharmaceuticals SA (Euronext Brussels:MITRA), which focuses on women's [...]

Published
2023

32. Mithra Pharmaceuticals granted new US patent extending NEXTSTELLIS protection until 2036

Subjects
Euronext Brussels S.A./N.V. -- Intellectual property, Drospirenone -- Intellectual property, Securities industry -- Intellectual property, Securities industry, Chemistry, Nextstellis (Contraceptive) -- Intellectual property
Abstract

M2 PHARMA-November 7, 2023-Mithra Pharmaceuticals granted new US patent extending NEXTSTELLIS protection until 2036 (C)2023 M2 COMMUNICATIONS Belgian biopharmaceutical company Mithra Pharmaceuticals SA (Euronext Brussels:MITRA), which focuses on women's health, [...]

Published
2023

33. Patent Issued for Synthetic progestogens and pharmaceutical compositions comprising the same (USPTO 11291633)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 APR 28 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Laboratorios Leon Farma SA (Leon, Spain) has been issued patent number 11291632, according to [...]

Published
2022

34. Patent Issued for Synthetic progestogens and pharmaceutical compositions comprising the same (USPTO 11291632)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 APR 28 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Laboratorios Leon Farma SA (Leon, Spain) has been issued patent number 11291632, according to [...]

Published
2022

35. 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same' in Patent Application Approval Process (USPTO 20220040113)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2022 MAR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors DROUIN, Dominique (Verrieres-le-Buisson, FR); PERRIN, Philippe (Paris, FR); [...]

Published
2022

36. 'Multiphasic Contraceptive Regimen For Oral Combination Drug Formulation Of Progestin And Estrogen' in Patent Application Approval Process (USPTO 20210346397)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Phenols -- Intellectual property, Norgestimate -- Intellectual property, Contraceptives -- Intellectual property, Drug approval, Estrogen, Health, Women's issues/gender studies
Abstract

2021 DEC 2 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventor RUBIN, Arkady (Flemington, NJ, US), filed on July [...]

Published
2021

37. Patent Application Titled 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same' Published Online (USPTO 20210299146)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2021 OCT 21 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

Published
2021

38. Patent Issued for Synthetic progestogens and pharmaceutical compositions comprising the same (USPTO 11123299)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2021 OCT 14 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent by the inventors Drouin, Dominique (Verrieres-le-Buisson, FR), Perrin, Philippe (Paris, FR), Velada, [...]

Published
2021

39. Patent Issued for Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen (USPTO 11103515)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Phenols -- Intellectual property, Norgestimate -- Intellectual property, Contraceptives -- Intellectual property, Estrogen, Health, Women's issues/gender studies
Abstract

2021 SEP 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent by the inventors Rubin, Arkady (Flemington, NJ, US), filed on December 10, [...]

Published
2021

40. 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same' in Patent Application Approval Process (USPTO 20210213035)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2021 AUG 5 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors DROUIN, Dominique (Verrieres-le-Buisson, FR); PERRIN, Philippe (Paris, FR); [...]

Published
2021

41. Patent Application Titled 'Synthetic Progestogens And Pharmaceutical Compositions Comprising The Same' Published Online (USPTO 20210128585)

Subjects
Women -- Health aspects, Drospirenone -- Intellectual property, Progesterone -- Intellectual property, Estrogen, Oral contraceptives -- Intellectual property, Health, Women's issues/gender studies
Abstract

2021 JUN 17 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

Published
2021

42. 'Stable Pharmaceutical Compositions Containing Estradiol And Progesterone For Oral Administration' in Patent Application Approval Process (USPTO 20210121480)

Subjects
United States. Food and Drug Administration, Women -- Health aspects, Estradiol -- Intellectual property, Drospirenone -- Intellectual property, Phenols -- Intellectual property, Conjugated estrogens -- Intellectual property, Progesterone -- Intellectual property, Norgestimate -- Intellectual property, Health, Women's issues/gender studies, Prometrium (Medication) -- Intellectual property
Abstract

2021 MAY 20 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors Prattipati, Vijayabhanu (Hyderabad, IN); Keesara, Venkateshwar Reddy (Hyderabad, [...]

Published
2021

43. Patent Issued for Estrogen Combination For Treatment Of Multiple Sclerosis (USPTO 10,799,512)

Subjects
Dienogest, Women's health, Norgestimate -- Intellectual property, Estrogens, Drospirenone -- Intellectual property, Fingolimod -- Intellectual property, Hydroxyprogesterone -- Intellectual property, Multiple sclerosis -- Development and progression, Phenols (Class of compounds) -- Intellectual property, Dimethyl fumarate, Teriflunomide, Health, Women's issues/gender studies
Abstract

2020 OCT 29 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- From Alexandria, Virginia, NewsRx journalists report that a patent by the inventor Voskuhl, Rhonda [...]

Published
2020

44. Patent Application Titled 'Multiphasic Contraceptive Regimen For Oral Combination Drug Formulation Of Progestin And Estrogen' Published Online (USPTO 20200147105)

Subjects
Dienogest, Women's health, Estrogens, Drospirenone -- Intellectual property, Contraceptives -- Intellectual property, Phenols (Class of compounds) -- Intellectual property, Oral contraceptives, Health, Editors, Norgestimate, Health, Women's issues/gender studies
Abstract

2020 JUN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

Published
2020

45. Patent Issued for Multiphasic Contraceptive Regimen For Oral Combination Drug Formulation Of Progestin And Estrogen (USPTO 10,537,582)

Subjects
Dienogest, Women's health, Estrogens, Drospirenone -- Intellectual property, Contraceptives -- Intellectual property, Phenols (Class of compounds) -- Intellectual property, Oral contraceptives, Health, Editors, Norgestimate, Health, Women's issues/gender studies
Abstract

2020 FEB 6 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by [...]

Published
2020

46. 'Process For Preparing Filled Hard-Shell Capsules With (Meth)acrylate Copolymer Based Coatings With A Capsule-Filling Machine' in Patent Application Approval Process (USPTO 20230088952)

Subjects
Pindolol -- Intellectual property, Drospirenone -- Intellectual property, Methamphetamine -- Intellectual property, Pantoprazole -- Intellectual property, Coatings -- Intellectual property, Cetrorelix -- Intellectual property, Business, Health
Abstract

2023 APR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Patent Business Week -- A patent application by the inventors Bar, Hans (Michelstadt, DE); Guha, Ashish (Mumbai, [...]

Published
2023

47. Australian Patent Office Decision: Bayer Pharma Aktiengesellschaft [2022] APO 7 (7 February 2022)

Subjects
Merck Sharp & Dohme Corp. -- Intellectual property, Drospirenone -- Intellectual property, Contraceptives -- Intellectual property, Patents, Ethinyl estradiol -- Intellectual property, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, News, opinion and commentary
Abstract

Canberra: Australian Patent Office has issued the following decision: AUSTRALIAN PATENT OFFICE Bayer Pharma Aktiengesellschaft [2022] APO 7 Patent: 780330 Title: Pharmaceutical combination of ethinylestradiol and drospirenone for use as [...]

Published
2022

48. Patent Issued for Multiphasic Contraceptive Regimen For Oral Combination Drug Formulation Of Progestin And Estrogen (USPTO 10,463,678)

Subjects
Dienogest, Women's health, Estrogens, Drospirenone -- Intellectual property, Contraceptives -- Intellectual property, Phenols (Class of compounds) -- Intellectual property, Oral contraceptives, Health, Editors, Norgestimate, Health, Women's issues/gender studies
Abstract

2019 NOV 21 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Arstat Inc. (Flemington, New Jersey, United States) has been issued patent number 10,463,678, according [...]

Published
2019

49. Patent Application Titled 'Multiphasic Contraceptive Regimen For Oral Combination Drug Formulation Of Progestin And Estrogen' Published Online (USPTO 20190282587)

Subjects
Dienogest, Women's health, Estrogens, Drospirenone -- Intellectual property, Contraceptives -- Intellectual property, Phenols (Class of compounds) -- Intellectual property, Oral contraceptives, Health, Editors, Health, Women's issues/gender studies
Abstract

2019 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

Published
2019

50. Patent Issued for Anti-Ar Agent And Radiation Therapy For Androgen Receptor Positive Cancer (USPTO 10,391,173)

Subjects
Physical fitness, Cancer, Enzalutamide, Abiraterone -- Intellectual property, Radiotherapy, Drospirenone -- Intellectual property, Radiation (Physics), Obesity, Anopheles, Editors, Health
Abstract

2019 SEP 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Cleveland Clinic Foundation (Cleveland, Ohio, United States) has been issued patent number [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results